Parkinson's disease is a debilitating neurodegenerative disease, affecting everything from speech, posture and gait to digestion, sleep, impulse control and cognition.
Parkinson's disease is a debilitating neurodegenerative disease, affecting everything from speech, posture and gait to digestion, sleep, impulse control and cognition. Therapies exist that alleviate some symptoms of the disease, but there is still no cure for Parkinson's, which affects close to one million Americans and 10 million people worldwide.
A new Tel Aviv University study unveils a novel method for detecting the aggregation of the protein alpha-synuclein, a hallmark of Parkinson's disease. With this knowledge, caregivers could introduce treatment that has the potential to significantly delay disease progression.
By the time a patient is diagnosed with Parkinson's disease, 50 percent to 80 percent of the dopaminergic cells in the part of the brain called substania nigra are already dead, possibly due to development of toxicity as result of alpha-synuclein aggregation. "We have developed a new method for tracking early stages of aggregation of alpha-synuclein using super-resolution microscopy and advanced analysis," says Prof. Uri Ashery, co-author of the study and head of TAU's Sagol School of Neuroscience and TAU's George S. Wise Faculty of Life Sciences. The research was published in Acta Neuropathologica on May 31.
Read more at: Tel Aviv University
Photo credit: geralt via Pixabay